Andrew Grethlein - Geron Executive VP of Devel. and Technical Operations
| GERN Stock | USD 2.56 0.23 8.24% |
EVP
Dr. Andrew J. Grethlein, Ph.D., is Principal Operating Officer, Executive Vice President of the Company. reviously, he served as our Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as our Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinologyoriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporationrationration, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation since 2019.
| Age | 61 |
| Tenure | 6 years |
| Address | 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404 |
| Phone | 650 473 7700 |
| Web | https://www.geron.com |
Geron Management Efficiency
The company has return on total asset (ROA) of (0.303) % which means that it has lost $0.303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6903) %, meaning that it created substantial loss on money invested by shareholders. Geron's management efficiency ratios could be used to measure how well Geron manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of February 2025, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.82. At this time, Geron's Total Assets are very stable compared to the past year. As of the 16th of February 2025, Non Current Assets Total is likely to grow to about 63.7 M, while Other Current Assets are likely to drop about 4 M.Similar Executives
| Found 2 records | EVP Age | ||
| Mark Boulding | PTC Therapeutics | 63 | |
| Neil Almstead | PTC Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.3 |
Geron Leadership Team
Elected by the shareholders, the Geron's board of directors comprises two types of representatives: Geron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Geron. The board's role is to monitor Geron's management team and ensure that shareholders' interests are well served. Geron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Geron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Faye MD, Executive Officer | ||
| Joseph MD, Research President | ||
| Stephen JD, Chief VP | ||
| Andrew Grethlein, Executive VP of Devel. and Technical Operations | ||
| Aron Feingold, Vice Communications | ||
| John MD, President Board | ||
| James MBA, Executive Officer | ||
| Michelle Robertson, CFO, VP | ||
| Anil Kapur, Executive Officer | ||
| Edward Koval, Executive Officer | ||
| Shannon Odam, Vice President - Human Resources | ||
| Melissa Behrs, Executive Vice President - Portfolio and Alliance Management | ||
| Olivia Bloom, CFO, Executive VP of Fin. and Treasurer | ||
| Scott Samuels, Chief VP |
Geron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Geron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 1.3 B | ||||
| Shares Outstanding | 604.5 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 82.25 % | ||||
| Number Of Shares Shorted | 74.57 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 5.29 X |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 171.384 | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.